Fish oil absorption study launches in healthy volunteers
NCT ID NCT07461649
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how a fish oil supplement (CreNeuroS® CNS Fish Oil Plus) is absorbed in the body at different dose levels. It involves 32 healthy adults who will take the supplement once and have their blood tested over several days. The goal is to measure the amount of the active ingredients in the blood, not to treat any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 32 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 45 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subjects who have no evidence of underlying disease during screening and check-in and whose screening is performed within 21 days of check in. * Subjects whose screening laboratory values are within normal limits are considered by the physician or principal/clinical investigator to be of no clinical significance. * Healthy as documented by the medical history, physical examination and vital examinations. * Generally healthy, as documented by a 12-lead electrocardiogram (ECG), Chest X-Ray and clinical laboratory assessments. * Willing to consume Ovo lacto-vegetarian diet. * Willing to comply with all requirements of this study protocol as well as instructions from the study personnel. * Generally healthy, as documented by gynaecological examination and breast examination (for female subjects). Exclusion Criteria: * Evidence of allergy or known hypersensitivity to Eicosapentaenoic Acid (EPA) and Calcium L-S-Methyltetrahydrofolate (L-S-MTHF) or its inactive ingredients. * Evidence of allergy to fish or shellfish. * Subjects with hepatic encephalopathy, cholestasis, myasthenia, pre-existing liver disease, alcohol abuse, existing tinnitus, and pre-existing gall bladder disease. * Any major illness in the last three months or any significant ongoing chronic medical illness. * Renal or liver impairment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bioavailability and pharmacokinetics are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Spinos Lifescience and Research Private Limited
Coimbatore, Tamil Nadu, 641029, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.